These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17443131)

  • 21. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
    Nordström AL; Nyberg S; Olsson H; Farde L
    Arch Gen Psychiatry; 1998 Mar; 55(3):283-4. PubMed ID: 9510228
    [No Abstract]   [Full Text] [Related]  

  • 22. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.
    Moresco RM; Cavallaro R; Messa C; Bravi D; Gobbo C; Galli L; Lucignani G; Colombo C; Rizzo G; Velonà I; Smeraldi E; Fazio F
    J Psychopharmacol; 2004 Sep; 18(3):355-65. PubMed ID: 15358979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
    J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
    Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine pamoate for the treatment of schizophrenia.
    Naber D
    Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
    Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
    Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
    J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
    Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.
    Detke HC; Zhao F; Garhyan P; Carlson J; McDonnell D
    Int Clin Psychopharmacol; 2011 Jan; 26(1):35-42. PubMed ID: 20948432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.